STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease
Brain Research · 2024-02 · 1824 · 148691
DOI: 10.1016/j.brainres.2023.148691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2024-02. Verfasst von Rupert D Smit und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience & Shriners Hospitals for Pediatric Research Center, Temple University, USA. Electronic address: rupert.smit@temple.edu. Hauptthemen laut MEDLINE: Parkinson Disease, Neuroprotective Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
INTRODUCTION: Parkinson's disease (PD) is the most prevalent disorder of the basal ganglia, propagated by the degeneration of axon terminals within the striatum and subsequent loss of dopaminergic neurons in the substantia nigra (SN). Exposure of environmental neurotoxins and mutations of several mitochondrial and proteasomal genes are primarily responsible. METHODS: To determine whether signal transducer and activator of transcription 3 (STAT3) could protect dopaminergic neurons against degeneration, we first screened it in the in vitro capacity using immortalized rat dopaminergic N27 cells under 6-OHDA neurotoxicity. We then evaluated the effectiveness of constitutively active (ca) STAT3 as a neuroprotective agent on N27 cells in a 6-hydroxydopamine (6-OHDA) induced rat model of PD and compared it to control animals or animals where AAV/caRheb was expressed in SN. Behavioral outcomes were assessed using rotational and cylinder assays and mitochondrial function using reactive oxygen species (ROS) levels. RESULTS: Using flow cytometry, the in vitro analysis determined caSTAT3 significantly decreased dopaminergic neuronal death under 6-OHDA treatment conditions. Importantly, in vivo overexpression of caSTAT3 in SN dopaminergic neurons using AAV-mediated expression demonstrated significant neuroprotection of dopaminergic neurons following 6-OHDA. Both caSTAT3 and caRheb + caSTAT3 co-injection into substantia nigra reduced D-amphetamine-induced rotational behavior and increased ipsilateral forelimb function when compared to control animals. In addition, caSTAT3 decreased mitochondrial ROS production following 6-OHDA induced neurotoxicity. CONCLUSION: caSTAT3 confers resistance against ROS production in mitochondria of susceptible SN dopaminergic neurons potentially offering a new avenue for treatment against PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience & Shriners Hospitals for Pediatric Research Center, Temple University, USA. Electronic address: rupert.smit@temple.edu.
- Department of Neuroscience & Shriners Hospitals for Pediatric Research Center, Temple University, USA.
- Fels Institute for Cancer Research & Molecular Biology, Temple University, USA.
- Flow Cytometry Core Facility, Temple University, USA.
Förderung
- NIAID NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Smit, R. D., Ghosh, B., Campion, T. J., Stingel, R., Lavell, E., Hooper, R., Fan, X., Soboloff, J., & Smith, G. M. (2024). STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease. Brain Research, 1824, 148691. https://doi.org/10.1016/j.brainres.2023.148691
Vancouver
Smit RD, Ghosh B, Campion TJ, Stingel R, Lavell E, Hooper R, et al. STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease. Brain Research. 2024;1824:148691. doi:10.1016/j.brainres.2023.148691
BibTeX
@article{Smit2024,
author = {Smit, Rupert D and Ghosh, Biswarup and Campion, Thomas J and Stingel, Rachel and Lavell, Emily and Hooper, Robert and Fan, Xiaoxuan and Soboloff, Jonathan and Smith, George M},
title = {STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson's disease},
journal = {Brain Research},
year = {2024},
volume = {1824},
pages = {148691},
doi = {10.1016/j.brainres.2023.148691}
}
EUVIMED